Effects of combined treatment with zibotentan and dapagliflozin compared to dapagliflozin alone in patients with diabetic and non‐diabetic chronic kidney disease

Documenti analoghi

• The effect of the endothelin receptor antagonist atrasentan on insulin resistance in phenotypic clusters of patients with type 2 diabetes and chronic kidney disease
  di: Johannes David Smeijer, et al.
  Pubblicazione: (2024)
• Aldosterone synthase inhibitor ( BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double‐blind, placebo‐controlled, Phase I trial
  di: Stefan R. Bornstein, et al.
  Pubblicazione: (2024)
• Dual add‐on therapy of gemigliptin and dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin alone: The SOLUTION 2 study
  di: Kyung Ah Han, et al.
  Pubblicazione: (2024)
• Effect of dapagliflozin on renal haemodynamics in hyperfiltering T2D patients
  di: Eugenio Cersosimo, et al.
  Pubblicazione: (2024)
• Cardiovascular and non‐renal complications of chronic kidney disease: Managing risk
  di: Peter Rossing, et al.
  Pubblicazione: (2024)